Inhibikase Therapeutics, Inc. (IKT)

NASDAQ: IKT · Real-Time Price · USD

1.660

-0.040 (-2.35%)

At close: Jun 20, 2025, 4:00 PM

1.690

+0.030 (1.81%)

After-hours: Jun 20, 2025, 5:23 PM EDT

Inhibikase Therapeutics Stock Forecast

Stock Price Forecast

The 2 analysts with 12-month price forecasts for Inhibikase Therapeutics stock have an average target of 8, which predicts a 381.93% increase from the current stock price of 1.66.

Price Target: $8 (+381.93%)

Analyst Consensus: Buy

Target	Low	Average	Median	High
Price	$8.00	$8.00	$8.00	$8.00
Change	+381.93%	+381.93%	+381.93%	+381.93%

* Price targets were last updated on Nov 8, 2024.

Analyst Ratings

The average analyst rating for Inhibikase Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Rating	Jan '25	Feb '25	Mar '25	Apr '25	May '25	Jun '25
Strong Buy	2	1	1	1	1	1
Buy	0	0	0	0	0	0
Hold	0	1	1	1	1	1
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	2	2	2	2	2	2

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Edward White HC Wainwright & Co.	HC Wainwright & Co.	Hold Reiterates n/a	Hold	Reiterates	n/a	n/a	Mar 28, 2025
Edward White HC Wainwright & Co.	HC Wainwright & Co.	Strong Buy → Hold Downgrades n/a	Strong Buy → Hold	Downgrades	n/a	n/a	Feb 12, 2025
Dennis Ding Jefferies	Jefferies	Strong Buy Initiates $8	Strong Buy	Initiates	$8	+381.93%	Nov 8, 2024
Edward White HC Wainwright & Co.	HC Wainwright & Co.	Strong Buy Maintains $15 → $5	Strong Buy	Maintains	$15 → $5	+201.20%	Oct 14, 2024
Edward White HC Wainwright & Co.	HC Wainwright & Co.	Strong Buy Maintains $23 → $15	Strong Buy	Maintains	$23 → $15	+803.61%	Aug 16, 2024

More Analyst Ratings

Financial Forecast

Revenue This Year

n/a

Revenue Next Year

n/a

EPS This Year

-0.46

from -1.16

EPS Next Year

-0.61

from -0.46

Fiscal Year	FY 2020	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026	FY 2027
Period Ending	Dec 31, 2020	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026	Dec 31, 2027
Revenue	698.47K	3.10M	123.44K	260.50K	-	-	-	-
Revenue Growth	-37.79%	343.92%	-96.02%	111.04%	-	-	-	-
EPS	-2.08	-4.87	-4.28	-3.16	-1.16	-0.46	-0.61	-0.56
EPS Growth	-	-	-	-	-	-	-	-
Forward PE	-	-	-	-	-	-	-	-
No. Analysts	-	-	-	-	-	4	4	4

Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue	2025	2026	2027
High	n/a	n/a	n/a
Avg	n/a	n/a	n/a
Low	n/a	n/a	n/a

Revenue Growth

Revenue Growth	2025	2026	2027
High	-	-	-
Avg	-	-	-
Low	-	-	-

EPS Forecast

EPS	2025	2026	2027
High	-0.46	-0.63	-0.58
Avg	-0.46	-0.61	-0.56
Low	-0.47	-0.59	-0.54

EPS Growth

EPS Growth	2025	2026	2027
High	-	-	-
Avg	-	-	-
Low	-	-	-

Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.